Takeda Pharmaceutical Statistics
Total Valuation
Takeda Pharmaceutical has a market cap or net worth of $66.42 billion. The enterprise value is $97.59 billion.
| Market Cap | 66.42B |
| Enterprise Value | 97.59B |
Important Dates
The last earnings date was Thursday, October 29, 2026, before market open.
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | Mar 31, 2026 |
Share Statistics
Takeda Pharmaceutical has 1.60 billion shares outstanding. The number of shares has decreased by -1.27% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.60B |
| Shares Change (YoY) | -1.27% |
| Shares Change (QoQ) | +0.99% |
| Owned by Insiders (%) | 0.12% |
| Owned by Institutions (%) | 50.70% |
| Float | 1.60B |
Valuation Ratios
The trailing PE ratio is 258.93 and the forward PE ratio is 19.22.
| PE Ratio | 258.93 |
| Forward PE | 19.22 |
| PS Ratio | 2.22 |
| Forward PS | 2.24 |
| PB Ratio | 1.41 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 15.18 |
| P/OCF Ratio | 11.96 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.22, with an EV/FCF ratio of 22.30.
| EV / Earnings | 375.95 |
| EV / Sales | 3.27 |
| EV / EBITDA | 11.22 |
| EV / EBIT | 19.74 |
| EV / FCF | 22.30 |
Financial Position
The company has a current ratio of 1.15, with a Debt / Equity ratio of 0.72.
| Current Ratio | 1.15 |
| Quick Ratio | 0.51 |
| Debt / Equity | 0.72 |
| Debt / EBITDA | 3.78 |
| Debt / FCF | 7.79 |
| Interest Coverage | 3.54 |
Financial Efficiency
Return on equity (ROE) is 0.56% and return on invested capital (ROIC) is 6.22%.
| Return on Equity (ROE) | 0.56% |
| Return on Assets (ROA) | 3.27% |
| Return on Invested Capital (ROIC) | 6.22% |
| Return on Capital Employed (ROCE) | 6.13% |
| Weighted Average Cost of Capital (WACC) | 4.27% |
| Revenue Per Employee | $635,023 |
| Profits Per Employee | $5,520 |
| Employee Count | 47,029 |
| Asset Turnover | 0.32 |
| Inventory Turnover | 1.21 |
Taxes
| Income Tax | -276.88M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +56.93% in the last 52 weeks. The beta is 0.10, so Takeda Pharmaceutical's price volatility has been lower than the market average.
| Beta (5Y) | 0.10 |
| 52-Week Price Change | +56.93% |
| 50-Day Moving Average | 19.00 |
| 200-Day Moving Average | 17.62 |
| Relative Strength Index (RSI) | 71.34 |
| Average Volume (20 Days) | 2,946,980 |
Short Selling Information
The latest short interest is 3.29 million, so 0.21% of the outstanding shares have been sold short.
| Short Interest | 3.29M |
| Short Previous Month | 4.20M |
| Short % of Shares Out | 0.21% |
| Short % of Float | 0.21% |
| Short Ratio (days to cover) | 1.21 |
Income Statement
In the last 12 months, Takeda Pharmaceutical had revenue of $29.86 billion and earned $259.59 million in profits. Earnings per share was $0.08.
| Revenue | 29.86B |
| Gross Profit | 19.34B |
| Operating Income | 4.95B |
| Pretax Income | -15.73M |
| Net Income | 259.59M |
| EBITDA | 8.69B |
| EBIT | 4.95B |
| Earnings Per Share (EPS) | $0.08 |
Balance Sheet
The company has $2.66 billion in cash and $34.09 billion in debt, with a net cash position of -$31.43 billion or -$19.67 per share.
| Cash & Cash Equivalents | 2.66B |
| Total Debt | 34.09B |
| Net Cash | -31.43B |
| Net Cash Per Share | -$19.67 |
| Equity (Book Value) | 47.20B |
| Book Value Per Share | 29.54 |
| Working Capital | 2.50B |
Cash Flow
In the last 12 months, operating cash flow was $5.55 billion and capital expenditures -$1.18 billion, giving a free cash flow of $4.38 billion.
| Operating Cash Flow | 5.55B |
| Capital Expenditures | -1.18B |
| Depreciation & Amortization | 3.72B |
| Net Borrowing | -1.87B |
| Free Cash Flow | 4.38B |
| FCF Per Share | $2.74 |
Margins
Gross margin is 64.77%, with operating and profit margins of 16.56% and 0.87%.
| Gross Margin | 64.77% |
| Operating Margin | 16.56% |
| Pretax Margin | -0.05% |
| Profit Margin | 0.87% |
| EBITDA Margin | 29.11% |
| EBIT Margin | 16.56% |
| FCF Margin | 14.77% |
Dividends & Yields
This stock pays an annual dividend of $0.49, which amounts to a dividend yield of 2.34%.
| Dividend Per Share | $0.49 |
| Dividend Yield | 2.34% |
| Dividend Growth (YoY) | -9.35% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 605.34% |
| FCF Payout Ratio | 17.97% |
| Buyback Yield | 1.27% |
| Shareholder Yield | 3.61% |
| Earnings Yield | 0.39% |
| FCF Yield | 6.59% |
Analyst Forecast
The average price target for Takeda Pharmaceutical is $23.00, which is 9.21% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $23.00 |
| Price Target Difference | 9.21% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 3.12% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Takeda Pharmaceutical has an Altman Z-Score of 1.21 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.21 |
| Piotroski F-Score | 6 |